The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: antibody encoding polynucleotide libraries. Buy the report here.
Smarter leaders trust GlobalData
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
80+ innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.
Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Antibody encoding polynucleotide libraries is a key innovation area in the pharmaceutical industry
Antibody encoding polynucleotide libraries are sets of genetic sequences that encode for different antibodies. These libraries can be used to identify antibodies with specific functions, such as binding to a particular antigen, and can be produced through in vitro or in vivo methods.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 60 companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of antibody encoding polynucleotide libraries.
Key players in antibody encoding polynucleotide libraries – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to antibody encoding polynucleotide libraries
Source: GlobalData Patent Analytics
Codexis is one of the leading patent filers in antibody encoding polynucleotide libraries. The company uses its Codex HiRev Isothermal Polymerase and Codex HiTemp Reverse Transcriptase platforms and content-rich libraries to design enzymes and antibodies.
In terms of application diversity, ViroCarb leads the pack, while HealthTell and Xencor stood in second and third positions, respectively. By means of geographic reach, Adimab held the top position, followed by Xencor and Glycosyn.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
